Interleukin 38 as a Biomarker for Metabolic Syndrome in Psoriatic Patients

Interleukin 38 as a Biomarker for Metabolic Syndrome in Psoriatic Patients

case control study to compare level of interleukin 38 in patients with psoriasis and patients with metabolic syndrome with healthy control subjects

this case control study will measure plasma level of interleukin 38 in 4 groups of 24 subject, group one will have psoriatic patients, group 2 will have psoriatic patients with metabolic syndrome, group three will have patients with metabolic syndrome only, and group 4 will have healthy control subjects.

Inclusion Criteria:

• specific to each group

Exclusion Criteria:

• Patient refusal. Age <18 years Pregnancy Lactation smoking Infections. Patients with other inflammatory skin disorders use of antioxidant and anti-inflammatory drugs patients on treatment for psoriasis